All In Biotech

Drug Trial Radar · NCT04926818

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

A 2-year Randomized, 3-arm, Double-blind, Non-inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Pediatric Patients With Multiple Sclerosis Followed by an Open-label Extension

Last checked: Nov 20, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 129 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

129

Actual

Start

Oct 5, 2021

Primary completion

Mar 25, 2026

Study completion Feb 28, 2031

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jun 15, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 10 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis

Conditions

  • Multiple Sclerosis (MS)

Interventions

  • FingolimodDrug

    Fingolimod capsule administered orally once daily at a dose of either 0.5 mg or 0.25 mg (depending on patient's body weight).

  • OfatumumabDrug

    Ofatumumab as a solution for injection in an autoinjector containing 20 mg ofatumumab (50 mg/mL, 0.4 mL content) for subcutaneous administration. A loading dose at Day1, Day 7 and Day 14 and then injections every 4 weeks/ 6 weeks (depending on patient's body weight).

  • SiponimodDrug

    Siponimod tablet administered orally once daily. Titration period, Day 1 to Day 6, first dose is either 0.1 mg or 0.25 mg up to daily dose of either 0.5 mg, 1 mg or 2 mg (depending on CYP2C9 genotype and body weight).

  • Fingolimod placeboOther

    Fingolimod matching placebo capsule

  • Siponimod placeboOther

    Siponimod matching placebo tablet

  • Ofatumumab placeboOther

    Ofatumumab matching placebo autoinjector

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized relapse rate (ARR) in target pediatric participantsTime frame: Baseline up to 24 months

Locations

51 sites in 25 countries. Site status is shown where the registry gives one.

  • Arkansas Childrens Hosp Rsch Inst

    Little Rock, Arkansas

  • Childrens Hospital Los Angeles

    Los Angeles, California

  • Childrens National Medical Center

    Washington D.C., District of Columbia

  • Axiom Clinical Research of Florida

    Tampa, Florida

  • Childrens Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Novartis Investigative Site

    CABA, Argentina

  • Novartis Investigative Site

    Parkville, Victoria, Australia

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Esneux, Belgium

  • Novartis Investigative Site

    Ghent, Belgium

  • Novartis Investigative Site

    Curitiba, Paraná, Brazil

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Lo Barnechea, Santiago Metropolitan, Chile

  • Novartis Investigative Site

    Zagreb, Croatia

  • Novartis Investigative Site

    Tallinn, Estonia

  • Novartis Investigative Site

    Le Kremlin-Bicêtre, France

  • Novartis Investigative Site

    Montpellier, France

  • Novartis Investigative Site

    Strasbourg, France

  • Novartis Investigative Site

    Bochum, Germany

  • Novartis Investigative Site

    Freiburg im Breisgau, Baden-Wurttemberg, Germany

  • Novartis Investigative Site

    Göttingen, Lower Saxony, Germany

  • Novartis Investigative Site

    Guatemala City, Guatemala

  • Novartis Investigative Site

    New Delhi, National Capital Territory of Delhi, India

  • Novartis Investigative Site

    Lucknow, Uttar Pradesh, India

  • Novartis Investigative Site

    Kolkata, West Bengal, India

  • Novartis Investigative Site

    Petah Tikva, Israel

  • Novartis Investigative Site

    Naples, Italy

  • Novartis Investigative Site

    Roma, RM, Italy

  • Novartis Investigative Site

    Riga, Latvia

  • Novartis Investigative Site

    Mexico City, Mexico City, Mexico

  • Novartis Investigative Site

    Mexico City, Mexico City, Mexico

  • Novartis Investigative Site

    Gdansk, Poland

  • Novartis Investigative Site

    Lodz, Poland

  • Novartis Investigative Site

    Poznan, Poland

  • Novartis Investigative Site

    Warsaw, Poland

  • Novartis Investigative Site

    Coimbra, Portugal

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.